http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 22 Jul 2026 06:53:21 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+PolyPid+Ltd.+%28PYPD%29/26797922.html <p>H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $13.00 price target on PolyPid Ltd. (NASDAQ: PYPD).</p><p>The analyst commented: "PYPD announced an exclusive licensing and collaboration agreement with Azurity Pharmaceuticals (Private) for D-PLEX100 in the U.S. and Canada. We view the agreement positively, as we have consistently viewed partnering D-PLEX100 commercialization as the optimal strategy for PYPD given the slower nature of hospital launches and the capital that would otherwise be required to build a commercial organization. PYPD will receive $15M upfront and another $15M following expected FDA acceptance of the NDA in August, with up to ~$320M in http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+PolyPid+Ltd.+%28PYPD%29/26797922.html Wed, 22 Jul 2026 06:53:21 -0400 PYPD http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PolyPid+Ltd.++++++++++++++For%3A+Jul+21/26792249.html si-local-file:///var/storage/secattach/20260721/26792249.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PolyPid+Ltd.++++++++++++++For%3A+Jul+21/26792249.html Tue, 21 Jul 2026 07:35:00 -0400 O.13797406 PYPD http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PolyPid+Ltd.++++++++++++++For%3A+Jul+21/26792249.html si-local-file:///var/storage/secattach/20260721/26792249.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PolyPid+Ltd.++++++++++++++For%3A+Jul+21/26792249.html Tue, 21 Jul 2026 07:35:00 -0400 O.13797406 PYPD http://www.streetinsider.com/Corporate+News/PolyPid+partners+with+Azurity+for+D-PLEX100+U.S.+and+Canada+rights/26792192.html <p>PolyPid Ltd. (NASDAQ: PYPD) has entered into an exclusive commercial partnership with Azurity Pharmaceuticals for the commercialization of D-PLEX100 in the United States and Canada, according to a company press release.</p><p>Under the agreement, PolyPid will receive a $15 million upfront payment upon signing and an additional $15 million milestone payment upon FDA acceptance of the D-PLEX100 New Drug Application, which is expected in August 2026. PolyPid is eligible to receive up to approximately $300 million in additional regulatory, development, and sales-based milestone payments, bringing the total potential value to more than $320 million. PolyPid will also receive tiered royalties ranging http://www.streetinsider.com/Corporate+News/PolyPid+partners+with+Azurity+for+D-PLEX100+U.S.+and+Canada+rights/26792192.html Tue, 21 Jul 2026 07:30:38 -0400 PYPD http://www.streetinsider.com/Press+Releases/PolyPid+Announces+Exclusive+Partnership+with+Azurity+Pharmaceuticals+for+the+Commercialization+of+D-PLEX%E2%82%81%E2%82%80%E2%82%80+in+the+U.S.+and+Canada+/26792153.html <ul><li style="margin-top:0cm; margin-bottom:10pt;">PolyPid to potentially receive over $320 million in upfront and milestone payments, including $30 million in upfront and near-term milestone payments, plus tiered royalties ranging from mid-teen to mid-twenties percentages</li><li style="margin-top:0cm; margin-bottom:10pt;">Azurity, a private global pharmaceutical company, to commercialize D-PLEX₁₀₀ upon approval in the U.S. and Canada for the prevention of surgical site infections, leveraging its first-in-class commercial model. PolyPid to manufacture and supply D-PLEX₁₀₀</li><li style="margin-top:0cm; margin-bottom:10pt;">Azurity will also fund clinical development of D-PLEX₁₀₀, supporting the potential label expansion in the U.S. and Canada beyond SSI indications for abdominal surgery</li><li style="margin-top:0cm; margin-bottom:10pt;">Partnership follows positive Phase 3 SHIELD II http://www.streetinsider.com/Press+Releases/PolyPid+Announces+Exclusive+Partnership+with+Azurity+Pharmaceuticals+for+the+Commercialization+of+D-PLEX%E2%82%81%E2%82%80%E2%82%80+in+the+U.S.+and+Canada+/26792153.html Tue, 21 Jul 2026 07:30:00 -0400 PYPD http://www.streetinsider.com/Globe+Newswire/PolyPid+Announces+Exclusive+Partnership+with+Azurity+Pharmaceuticals+for+the+Commercialization+of+D-PLEX%E2%82%81%E2%82%80%E2%82%80+in+the+U.S.+and+Canada+/26792153.html <ul><li style="margin-top:0cm; margin-bottom:10pt;">PolyPid to potentially receive over $320 million in upfront and milestone payments, including $30 million in upfront and near-term milestone payments, plus tiered royalties ranging from mid-teen to mid-twenties percentages</li><li style="margin-top:0cm; margin-bottom:10pt;">Azurity, a private global pharmaceutical company, to commercialize D-PLEX₁₀₀ upon approval in the U.S. and Canada for the prevention of surgical site infections, leveraging its first-in-class commercial model. PolyPid to manufacture and supply D-PLEX₁₀₀</li><li style="margin-top:0cm; margin-bottom:10pt;">Azurity will also fund clinical development of D-PLEX₁₀₀, supporting the potential label expansion in the U.S. and Canada beyond SSI indications for abdominal surgery</li><li style="margin-top:0cm; margin-bottom:10pt;">Partnership follows positive Phase 3 SHIELD II http://www.streetinsider.com/Globe+Newswire/PolyPid+Announces+Exclusive+Partnership+with+Azurity+Pharmaceuticals+for+the+Commercialization+of+D-PLEX%E2%82%81%E2%82%80%E2%82%80+in+the+U.S.+and+Canada+/26792153.html Tue, 21 Jul 2026 07:30:00 -0400 PYPD http://www.streetinsider.com/Press+Releases/PolyPid+Announces+Exclusive+Partnership+with+Azurity+Pharmaceuticals+for+the+Commercialization+of+D-PLEX%E2%82%81%E2%82%80%E2%82%80+in+the+U.S.+and+Canada/26792173.html <ul><li style="margin-top:0cm; margin-bottom:10pt;">PolyPid to potentially receive over $320 million in upfront and milestone payments, including $30 million in upfront and near-term milestone payments, plus tiered royalties ranging from mid-teen to mid-twenties percentages</li><li style="margin-top:0cm; margin-bottom:10pt;">Azurity, a private global pharmaceutical company, to commercialize D-PLEX100 upon approval in the U.S. and Canada for the prevention of surgical site infections, leveraging its first-in-class commercial model. PolyPid to manufacture and supply D-PLEX100</li><li style="margin-top:0cm; margin-bottom:10pt;">Azurity will also fund clinical development of D-PLEX100, supporting the potential label expansion in the U.S. and Canada beyond SSI indications for abdominal surgery</li><li style="margin-top:0cm; margin-bottom:10pt;">Partnership follows positive Phase 3 SHIELD II http://www.streetinsider.com/Press+Releases/PolyPid+Announces+Exclusive+Partnership+with+Azurity+Pharmaceuticals+for+the+Commercialization+of+D-PLEX%E2%82%81%E2%82%80%E2%82%80+in+the+U.S.+and+Canada/26792173.html Tue, 21 Jul 2026 07:30:00 -0400 A.04758039 A.06822034 O.13797406 O.20026344 O.47642696 PYPD http://www.streetinsider.com/Press+Releases/PolyPid+Announces+Exclusive+Partnership+with+Azurity+Pharmaceuticals+for+the+Commercialization+of+D-PLEX%E2%82%81%E2%82%80%E2%82%80+in+the+U.S.+and+Canada/26792173.html <ul><li style="margin-top:0cm; margin-bottom:10pt;">PolyPid to potentially receive over $320 million in upfront and milestone payments, including $30 million in upfront and near-term milestone payments, plus tiered royalties ranging from mid-teen to mid-twenties percentages</li><li style="margin-top:0cm; margin-bottom:10pt;">Azurity, a private global pharmaceutical company, to commercialize D-PLEX100 upon approval in the U.S. and Canada for the prevention of surgical site infections, leveraging its first-in-class commercial model. PolyPid to manufacture and supply D-PLEX100</li><li style="margin-top:0cm; margin-bottom:10pt;">Azurity will also fund clinical development of D-PLEX100, supporting the potential label expansion in the U.S. and Canada beyond SSI indications for abdominal surgery</li><li style="margin-top:0cm; margin-bottom:10pt;">Partnership follows positive Phase 3 SHIELD II http://www.streetinsider.com/Press+Releases/PolyPid+Announces+Exclusive+Partnership+with+Azurity+Pharmaceuticals+for+the+Commercialization+of+D-PLEX%E2%82%81%E2%82%80%E2%82%80+in+the+U.S.+and+Canada/26792173.html Tue, 21 Jul 2026 07:30:00 -0400 A.04758039 A.06822034 O.13797406 O.20026344 O.47642696 PYPD http://www.streetinsider.com/Press+Releases/PolyPid+Announces+Exclusive+Partnership+with+Azurity+Pharmaceuticals+for+the+Commercialization+of+D-PLEX%E2%82%81%E2%82%80%E2%82%80+in+the+U.S.+and+Canada/26792173.html <ul><li style="margin-top:0cm; margin-bottom:10pt;">PolyPid to potentially receive over $320 million in upfront and milestone payments, including $30 million in upfront and near-term milestone payments, plus tiered royalties ranging from mid-teen to mid-twenties percentages</li><li style="margin-top:0cm; margin-bottom:10pt;">Azurity, a private global pharmaceutical company, to commercialize D-PLEX100 upon approval in the U.S. and Canada for the prevention of surgical site infections, leveraging its first-in-class commercial model. PolyPid to manufacture and supply D-PLEX100</li><li style="margin-top:0cm; margin-bottom:10pt;">Azurity will also fund clinical development of D-PLEX100, supporting the potential label expansion in the U.S. and Canada beyond SSI indications for abdominal surgery</li><li style="margin-top:0cm; margin-bottom:10pt;">Partnership follows positive Phase 3 SHIELD II http://www.streetinsider.com/Press+Releases/PolyPid+Announces+Exclusive+Partnership+with+Azurity+Pharmaceuticals+for+the+Commercialization+of+D-PLEX%E2%82%81%E2%82%80%E2%82%80+in+the+U.S.+and+Canada/26792173.html Tue, 21 Jul 2026 07:30:00 -0400 A.04758039 A.06822034 O.13797406 O.20026344 O.47642696 PYPD http://www.streetinsider.com/Press+Releases/PolyPid+Announces+Exclusive+Partnership+with+Azurity+Pharmaceuticals+for+the+Commercialization+of+D-PLEX%E2%82%81%E2%82%80%E2%82%80+in+the+U.S.+and+Canada/26792173.html <ul><li style="margin-top:0cm; margin-bottom:10pt;">PolyPid to potentially receive over $320 million in upfront and milestone payments, including $30 million in upfront and near-term milestone payments, plus tiered royalties ranging from mid-teen to mid-twenties percentages</li><li style="margin-top:0cm; margin-bottom:10pt;">Azurity, a private global pharmaceutical company, to commercialize D-PLEX100 upon approval in the U.S. and Canada for the prevention of surgical site infections, leveraging its first-in-class commercial model. PolyPid to manufacture and supply D-PLEX100</li><li style="margin-top:0cm; margin-bottom:10pt;">Azurity will also fund clinical development of D-PLEX100, supporting the potential label expansion in the U.S. and Canada beyond SSI indications for abdominal surgery</li><li style="margin-top:0cm; margin-bottom:10pt;">Partnership follows positive Phase 3 SHIELD II http://www.streetinsider.com/Press+Releases/PolyPid+Announces+Exclusive+Partnership+with+Azurity+Pharmaceuticals+for+the+Commercialization+of+D-PLEX%E2%82%81%E2%82%80%E2%82%80+in+the+U.S.+and+Canada/26792173.html Tue, 21 Jul 2026 07:30:00 -0400 A.04758039 A.06822034 O.13797406 O.20026344 O.47642696 PYPD http://www.streetinsider.com/Press+Releases/PolyPid+Announces+Exclusive+Partnership+with+Azurity+Pharmaceuticals+for+the+Commercialization+of+D-PLEX%E2%82%81%E2%82%80%E2%82%80+in+the+U.S.+and+Canada/26792173.html <ul><li style="margin-top:0cm; margin-bottom:10pt;">PolyPid to potentially receive over $320 million in upfront and milestone payments, including $30 million in upfront and near-term milestone payments, plus tiered royalties ranging from mid-teen to mid-twenties percentages</li><li style="margin-top:0cm; margin-bottom:10pt;">Azurity, a private global pharmaceutical company, to commercialize D-PLEX100 upon approval in the U.S. and Canada for the prevention of surgical site infections, leveraging its first-in-class commercial model. PolyPid to manufacture and supply D-PLEX100</li><li style="margin-top:0cm; margin-bottom:10pt;">Azurity will also fund clinical development of D-PLEX100, supporting the potential label expansion in the U.S. and Canada beyond SSI indications for abdominal surgery</li><li style="margin-top:0cm; margin-bottom:10pt;">Partnership follows positive Phase 3 SHIELD II http://www.streetinsider.com/Press+Releases/PolyPid+Announces+Exclusive+Partnership+with+Azurity+Pharmaceuticals+for+the+Commercialization+of+D-PLEX%E2%82%81%E2%82%80%E2%82%80+in+the+U.S.+and+Canada/26792173.html Tue, 21 Jul 2026 07:30:00 -0400 A.04758039 A.06822034 O.13797406 O.20026344 O.47642696 PYPD http://www.streetinsider.com/Press+Releases/PolyPid+Announces+Exclusive+Partnership+with+Azurity+Pharmaceuticals+for+the+Commercialization+of+D-PLEX%E2%82%81%E2%82%80%E2%82%80+in+the+U.S.+and+Canada/26792173.html <ul><li style="margin-top:0cm; margin-bottom:10pt;">PolyPid to potentially receive over $320 million in upfront and milestone payments, including $30 million in upfront and near-term milestone payments, plus tiered royalties ranging from mid-teen to mid-twenties percentages</li><li style="margin-top:0cm; margin-bottom:10pt;">Azurity, a private global pharmaceutical company, to commercialize D-PLEX100 upon approval in the U.S. and Canada for the prevention of surgical site infections, leveraging its first-in-class commercial model. PolyPid to manufacture and supply D-PLEX100</li><li style="margin-top:0cm; margin-bottom:10pt;">Azurity will also fund clinical development of D-PLEX100, supporting the potential label expansion in the U.S. and Canada beyond SSI indications for abdominal surgery</li><li style="margin-top:0cm; margin-bottom:10pt;">Partnership follows positive Phase 3 SHIELD II http://www.streetinsider.com/Press+Releases/PolyPid+Announces+Exclusive+Partnership+with+Azurity+Pharmaceuticals+for+the+Commercialization+of+D-PLEX%E2%82%81%E2%82%80%E2%82%80+in+the+U.S.+and+Canada/26792173.html Tue, 21 Jul 2026 07:30:00 -0400 A.04758039 A.06822034 O.13797406 O.20026344 O.47642696 PYPD http://www.streetinsider.com/Globe+Newswire/PolyPid+Announces+Exclusive+Partnership+with+Azurity+Pharmaceuticals+for+the+Commercialization+of+D-PLEX%E2%82%81%E2%82%80%E2%82%80+in+the+U.S.+and+Canada/26792173.html <ul><li style="margin-top:0cm; margin-bottom:10pt;">PolyPid to potentially receive over $320 million in upfront and milestone payments, including $30 million in upfront and near-term milestone payments, plus tiered royalties ranging from mid-teen to mid-twenties percentages</li><li style="margin-top:0cm; margin-bottom:10pt;">Azurity, a private global pharmaceutical company, to commercialize D-PLEX100 upon approval in the U.S. and Canada for the prevention of surgical site infections, leveraging its first-in-class commercial model. PolyPid to manufacture and supply D-PLEX100</li><li style="margin-top:0cm; margin-bottom:10pt;">Azurity will also fund clinical development of D-PLEX100, supporting the potential label expansion in the U.S. and Canada beyond SSI indications for abdominal surgery</li><li style="margin-top:0cm; margin-bottom:10pt;">Partnership follows positive Phase 3 SHIELD II http://www.streetinsider.com/Globe+Newswire/PolyPid+Announces+Exclusive+Partnership+with+Azurity+Pharmaceuticals+for+the+Commercialization+of+D-PLEX%E2%82%81%E2%82%80%E2%82%80+in+the+U.S.+and+Canada/26792173.html Tue, 21 Jul 2026 07:30:00 -0400 A.04758039 A.06822034 O.13797406 O.20026344 O.47642696 PYPD http://www.streetinsider.com/Globe+Newswire/PolyPid+Announces+Exclusive+Partnership+with+Azurity+Pharmaceuticals+for+the+Commercialization+of+D-PLEX%E2%82%81%E2%82%80%E2%82%80+in+the+U.S.+and+Canada/26792173.html <ul><li style="margin-top:0cm; margin-bottom:10pt;">PolyPid to potentially receive over $320 million in upfront and milestone payments, including $30 million in upfront and near-term milestone payments, plus tiered royalties ranging from mid-teen to mid-twenties percentages</li><li style="margin-top:0cm; margin-bottom:10pt;">Azurity, a private global pharmaceutical company, to commercialize D-PLEX100 upon approval in the U.S. and Canada for the prevention of surgical site infections, leveraging its first-in-class commercial model. PolyPid to manufacture and supply D-PLEX100</li><li style="margin-top:0cm; margin-bottom:10pt;">Azurity will also fund clinical development of D-PLEX100, supporting the potential label expansion in the U.S. and Canada beyond SSI indications for abdominal surgery</li><li style="margin-top:0cm; margin-bottom:10pt;">Partnership follows positive Phase 3 SHIELD II http://www.streetinsider.com/Globe+Newswire/PolyPid+Announces+Exclusive+Partnership+with+Azurity+Pharmaceuticals+for+the+Commercialization+of+D-PLEX%E2%82%81%E2%82%80%E2%82%80+in+the+U.S.+and+Canada/26792173.html Tue, 21 Jul 2026 07:30:00 -0400 A.04758039 A.06822034 O.13797406 O.20026344 O.47642696 PYPD http://www.streetinsider.com/Globe+Newswire/PolyPid+Announces+Exclusive+Partnership+with+Azurity+Pharmaceuticals+for+the+Commercialization+of+D-PLEX%E2%82%81%E2%82%80%E2%82%80+in+the+U.S.+and+Canada/26792173.html <ul><li style="margin-top:0cm; margin-bottom:10pt;">PolyPid to potentially receive over $320 million in upfront and milestone payments, including $30 million in upfront and near-term milestone payments, plus tiered royalties ranging from mid-teen to mid-twenties percentages</li><li style="margin-top:0cm; margin-bottom:10pt;">Azurity, a private global pharmaceutical company, to commercialize D-PLEX100 upon approval in the U.S. and Canada for the prevention of surgical site infections, leveraging its first-in-class commercial model. PolyPid to manufacture and supply D-PLEX100</li><li style="margin-top:0cm; margin-bottom:10pt;">Azurity will also fund clinical development of D-PLEX100, supporting the potential label expansion in the U.S. and Canada beyond SSI indications for abdominal surgery</li><li style="margin-top:0cm; margin-bottom:10pt;">Partnership follows positive Phase 3 SHIELD II http://www.streetinsider.com/Globe+Newswire/PolyPid+Announces+Exclusive+Partnership+with+Azurity+Pharmaceuticals+for+the+Commercialization+of+D-PLEX%E2%82%81%E2%82%80%E2%82%80+in+the+U.S.+and+Canada/26792173.html Tue, 21 Jul 2026 07:30:00 -0400 A.04758039 A.06822034 O.13797406 O.20026344 O.47642696 PYPD http://www.streetinsider.com/Globe+Newswire/PolyPid+Announces+Exclusive+Partnership+with+Azurity+Pharmaceuticals+for+the+Commercialization+of+D-PLEX%E2%82%81%E2%82%80%E2%82%80+in+the+U.S.+and+Canada/26792173.html <ul><li style="margin-top:0cm; margin-bottom:10pt;">PolyPid to potentially receive over $320 million in upfront and milestone payments, including $30 million in upfront and near-term milestone payments, plus tiered royalties ranging from mid-teen to mid-twenties percentages</li><li style="margin-top:0cm; margin-bottom:10pt;">Azurity, a private global pharmaceutical company, to commercialize D-PLEX100 upon approval in the U.S. and Canada for the prevention of surgical site infections, leveraging its first-in-class commercial model. PolyPid to manufacture and supply D-PLEX100</li><li style="margin-top:0cm; margin-bottom:10pt;">Azurity will also fund clinical development of D-PLEX100, supporting the potential label expansion in the U.S. and Canada beyond SSI indications for abdominal surgery</li><li style="margin-top:0cm; margin-bottom:10pt;">Partnership follows positive Phase 3 SHIELD II http://www.streetinsider.com/Globe+Newswire/PolyPid+Announces+Exclusive+Partnership+with+Azurity+Pharmaceuticals+for+the+Commercialization+of+D-PLEX%E2%82%81%E2%82%80%E2%82%80+in+the+U.S.+and+Canada/26792173.html Tue, 21 Jul 2026 07:30:00 -0400 A.04758039 A.06822034 O.13797406 O.20026344 O.47642696 PYPD http://www.streetinsider.com/Globe+Newswire/PolyPid+Announces+Exclusive+Partnership+with+Azurity+Pharmaceuticals+for+the+Commercialization+of+D-PLEX%E2%82%81%E2%82%80%E2%82%80+in+the+U.S.+and+Canada/26792173.html <ul><li style="margin-top:0cm; margin-bottom:10pt;">PolyPid to potentially receive over $320 million in upfront and milestone payments, including $30 million in upfront and near-term milestone payments, plus tiered royalties ranging from mid-teen to mid-twenties percentages</li><li style="margin-top:0cm; margin-bottom:10pt;">Azurity, a private global pharmaceutical company, to commercialize D-PLEX100 upon approval in the U.S. and Canada for the prevention of surgical site infections, leveraging its first-in-class commercial model. PolyPid to manufacture and supply D-PLEX100</li><li style="margin-top:0cm; margin-bottom:10pt;">Azurity will also fund clinical development of D-PLEX100, supporting the potential label expansion in the U.S. and Canada beyond SSI indications for abdominal surgery</li><li style="margin-top:0cm; margin-bottom:10pt;">Partnership follows positive Phase 3 SHIELD II http://www.streetinsider.com/Globe+Newswire/PolyPid+Announces+Exclusive+Partnership+with+Azurity+Pharmaceuticals+for+the+Commercialization+of+D-PLEX%E2%82%81%E2%82%80%E2%82%80+in+the+U.S.+and+Canada/26792173.html Tue, 21 Jul 2026 07:30:00 -0400 A.04758039 A.06822034 O.13797406 O.20026344 O.47642696 PYPD http://www.streetinsider.com/Globe+Newswire/PolyPid+Announces+Exclusive+Partnership+with+Azurity+Pharmaceuticals+for+the+Commercialization+of+D-PLEX%E2%82%81%E2%82%80%E2%82%80+in+the+U.S.+and+Canada/26792173.html <ul><li style="margin-top:0cm; margin-bottom:10pt;">PolyPid to potentially receive over $320 million in upfront and milestone payments, including $30 million in upfront and near-term milestone payments, plus tiered royalties ranging from mid-teen to mid-twenties percentages</li><li style="margin-top:0cm; margin-bottom:10pt;">Azurity, a private global pharmaceutical company, to commercialize D-PLEX100 upon approval in the U.S. and Canada for the prevention of surgical site infections, leveraging its first-in-class commercial model. PolyPid to manufacture and supply D-PLEX100</li><li style="margin-top:0cm; margin-bottom:10pt;">Azurity will also fund clinical development of D-PLEX100, supporting the potential label expansion in the U.S. and Canada beyond SSI indications for abdominal surgery</li><li style="margin-top:0cm; margin-bottom:10pt;">Partnership follows positive Phase 3 SHIELD II http://www.streetinsider.com/Globe+Newswire/PolyPid+Announces+Exclusive+Partnership+with+Azurity+Pharmaceuticals+for+the+Commercialization+of+D-PLEX%E2%82%81%E2%82%80%E2%82%80+in+the+U.S.+and+Canada/26792173.html Tue, 21 Jul 2026 07:30:00 -0400 A.04758039 A.06822034 O.13797406 O.20026344 O.47642696 PYPD http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PolyPid+Ltd.++++++++++++++For%3A+May+11++Filed+by%3A+Warshavsky+Ori/26784349.html si-local-file:///var/storage/secattach/20260717/26784349.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PolyPid+Ltd.++++++++++++++For%3A+May+11++Filed+by%3A+Warshavsky+Ori/26784349.html Fri, 17 Jul 2026 16:05:00 -0400 O.13797406 PYPD http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PolyPid+Ltd.++++++++++++++For%3A+May+11++Filed+by%3A+Warshavsky+Ori/26784349.html si-local-file:///var/storage/secattach/20260717/26784349.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PolyPid+Ltd.++++++++++++++For%3A+May+11++Filed+by%3A+Warshavsky+Ori/26784349.html Fri, 17 Jul 2026 16:05:00 -0400 O.13797406 PYPD http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PolyPid+Ltd.++++++++++++++For%3A+May+11++Filed+by%3A+Missulawin+Jonathan/26784312.html si-local-file:///var/storage/secattach/20260717/26784312.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PolyPid+Ltd.++++++++++++++For%3A+May+11++Filed+by%3A+Missulawin+Jonathan/26784312.html Fri, 17 Jul 2026 16:04:00 -0400 O.13797406 PYPD http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PolyPid+Ltd.++++++++++++++For%3A+May+11++Filed+by%3A+Missulawin+Jonathan/26784312.html si-local-file:///var/storage/secattach/20260717/26784312.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PolyPid+Ltd.++++++++++++++For%3A+May+11++Filed+by%3A+Missulawin+Jonathan/26784312.html Fri, 17 Jul 2026 16:04:00 -0400 O.13797406 PYPD http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PolyPid+Ltd.++++++++++++++For%3A+May+11++Filed+by%3A+Hazan+Dalit+Fellous/26784313.html si-local-file:///var/storage/secattach/20260717/26784313.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PolyPid+Ltd.++++++++++++++For%3A+May+11++Filed+by%3A+Hazan+Dalit+Fellous/26784313.html Fri, 17 Jul 2026 16:04:00 -0400 O.13797406 PYPD http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PolyPid+Ltd.++++++++++++++For%3A+May+11++Filed+by%3A+Hazan+Dalit+Fellous/26784313.html si-local-file:///var/storage/secattach/20260717/26784313.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PolyPid+Ltd.++++++++++++++For%3A+May+11++Filed+by%3A+Hazan+Dalit+Fellous/26784313.html Fri, 17 Jul 2026 16:04:00 -0400 O.13797406 PYPD http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PolyPid+Ltd.++++++++++++++For%3A+Jul+15++Filed+by%3A+Dror-Darwish+Nir/26784293.html si-local-file:///var/storage/secattach/20260717/26784293.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PolyPid+Ltd.++++++++++++++For%3A+Jul+15++Filed+by%3A+Dror-Darwish+Nir/26784293.html Fri, 17 Jul 2026 16:03:00 -0400 O.13797406 PYPD